Isofol Medical (ISOFOL) Q4 2025 earnings summary

Executive summary

• Ongoing phase Ib/II clinical study of arfolitixorin in metastatic colorectal cancer, with presentations at major oncology conferences (ESMO, ASCO-GI) highlighting study design and recruitment status.

• European Patent Office granted new product patent for arfolitixorin, securing protection until 2043.

• Strategic collaboration with Solasia Pharma K.K. to expand clinical studies into Japan, broadening patient diversity and regulatory reach.

Financial highlights

• Net revenue was SEK 0 for both Q4 and full year 2025, unchanged from 2024.

• Q4 2025 net loss was SEK -12.8 million, a slight improvement from SEK -13.1 million in Q4 2024.

• Full year 2025 net loss increased to SEK -54.2 million from SEK -43.5 million in 2024.

• Cash and cash equivalents at year-end were SEK 127.0 million, up from SEK 96.2 million, supported by a SEK 84.1 million rights issue.

• Equity at year-end was SEK 107.9 million, up from SEK 77.9 million.

Outlook and guidance

• Phase II study of arfolitixorin expected to begin later in 2026, with further study updates anticipated in Q1 2026.

• Continued focus on advancing arfolitixorin, regulatory interactions, and strategic partnerships, with multiple milestones expected in 2026.

• Board proposes no dividend for 2025.